Should Investors Be Worried About Dividend King AbbVie?
Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq. AbbVie beat Wall Street's top- and bottom-line estimates. The company also raised its full-year earnings guidance. However, two dark clouds loom over AbbVie that those Q1 numbers don't reflect. Should investors be worried about this healthcare Dividend King?None of the Trump administration's tariffs have afected AbbVie so far. That's because the across-the-board tariffs exempted pharmaceuticals. Don't count on seeing this protection last too much longer, though. Continue reading
Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq. AbbVie beat Wall Street's top- and bottom-line estimates. The company also raised its full-year earnings guidance.
However, two dark clouds loom over AbbVie that those Q1 numbers don't reflect. Should investors be worried about this healthcare Dividend King?
None of the Trump administration's tariffs have afected AbbVie so far. That's because the across-the-board tariffs exempted pharmaceuticals. Don't count on seeing this protection last too much longer, though.
